Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating datopotamab deruxtecan (Dato-DXd) with or without osimertinib vs platinum-based chemotherapy in EGFR-mutated locally advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)
• Osimertinib (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING